Featuring guest faculty, Adam Friedman, MD For the lunch time product theater, Dr. Adam Friedman presented a conversation on primary hyperhidrosis and treatment with Qbrexza. Qbrexza is the first and only FDA approved once daily topical anticholinergic cloth towelette indicated for the treatment of primary axillary hyperhidrosis in people 9 years of age and older. …
Hyperhidrosis, excessive sweating, is a condition that affects about 15 million people in the US alone. While it is mostly a cosmetic concern, it has been linked to quality of life factors such as anxiety and depression. Treatment options include approaches that block sweat from reaching the skin surface, destroy sweat glands entirely, or inhibit …
Excessive sweating (hyperhidrosis) occurs in up to 3% of the population and can be seen all over the body or localized to the axilla, palms or feet (Primary focal hyperhidrosis, PFH). However, the condition can also be seen in the face or scalp area (craniofacial hyperhidrosis). A recent study sought to characterize this issue in …
There are few options for topical treatment of hyperhidrosis that are currently on the market. The most common, topical aluminum chloride, has limited efficacy and can cause skin irritation. Using oral anticholinergic treatments can work, but come with risks of side effects such as xerostomia and constipation. A recent pilot study looked at the use …